PYGOPUS2 expression in prostatic adenocarcinoma is a potential risk stratification marker for PSA progression following radical prostatectomy. Issue 5 (18th September 2017)

• Record Type: Journal Article
• Authors: Kao, Kenneth R; Popadiuk, Paul; Thoms, John; Aoki, Satoko; Anwar, Shahgul; Fitzgerald, Emily; Andrews, Phillip; Voisey, Kim; Gai, Luis; Challa, Satya; He, Zhijian; Gonzales-Aguirre, Paola; Simmonds, Andrea; Popadiuk, Catherine
• Is Part Of: Journal of clinical pathology. Volume 71:Issue 5(2018)
• Page Start: 402
• Page End: 411
• Publication Date: 2017-09-18
• Subjects: prostatectomy -- recurrence -- immunohistochemistry -- biomarker; Pathology -- Periodicals; Pathology, Molecular -- Periodicals; 616.0705
• DOI: 10.1136/jclinpath-2017-204718
• Languages: English
• ISSNs: 0021-9746

Abstract

Abstract : Aims: Prostate cancer (PrCa) is the most frequently diagnosed non-cutaneous cancer in men. Without clear pathological indicators of disease trajectory at diagnosis, management of PrCa is challenging, given its wide-ranging manifestation from indolent to highly aggressive disease. This study examines the role in PrCa of the Pygopus (PYGO)2 chromatin effector protein as a risk stratification marker in PrCa. Methods: RNA expression was performed in PrCa cell lines using Northern and RT-PCR analyses. Protein levels were assessed using immunoblot and immunofluorescence. Immunohistochemistry was performed on tissue microarrays constructed from radical prostatectomies with 5-year patient follow-up data including Gleason score tumour staging, margin and lymph node involvement and prostate serum antigen (PSA) levels. Biochemical recurrence (BR) was defined as a postoperative PSA level of >0.2 nL. Univariate and multivariate analyses were performed using SAS and Kaplan-Meier curves using graphPad (Prism). Results: In vitro depletion of PYGO2 by RNAi in both androgen receptor positive and negative PrCa cell lines attenuated growth and reduced Ki67 and 47S rRNA expression, while PYGO2 protein was localised to the nuclei of tumours as determined by immunohistochemistry. High expression levels of PYGO2 in tumours (n=156) were correlated with BR identified as PSA progression, after 7-year follow-up independent of other traditional risk factors. Most importantly, high PYGO2 levels in intermediate grade tumours suggested increased risk of recurrence over those with negative or weak expression. Conclusion: Our data suggest that elevated PYGO2 expression in primary prostate adenocarcinoma is a potential risk factor for BR.